MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

24.02 2.74

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

23.12

Máximo

24.14

Métricas clave
By Trading Economics
Ingresos	675K 53M
Ventas	1.8M 148M
P/B Media del Sector	13.275 89.037
Margen de beneficios	35.57
Empleados	181
EBITDA	1.7M 80M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+49.78% upside

Dividendos
By Dow Jones
Próximas Ganancias	25 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	166M 2.8B
Apertura anterior	21.28
Cierre anterior	24.02

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

159 / 361 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 ene 2026, 23:49 UTC

Principales Movimientos del Mercado

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 ene 2026, 21:12 UTC

Principales Movimientos del Mercado

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 ene 2026, 21:00 UTC

Adquisiciones, fusiones, absorciones

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 ene 2026, 20:29 UTC

Principales Movimientos del Mercado

Chip Makers Gain After Trump Calls Off European Tariffs

21 ene 2026, 20:04 UTC

Principales Movimientos del Mercado

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 ene 2026, 23:34 UTC

Charlas de Mercado

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 ene 2026, 22:39 UTC

Ganancias

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 ene 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

21 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 ene 2026, 21:35 UTC

Adquisiciones, fusiones, absorciones

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 ene 2026, 21:19 UTC

Ganancias

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 ene 2026, 20:45 UTC

Adquisiciones, fusiones, absorciones

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 ene 2026, 20:36 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 ene 2026, 20:31 UTC

Charlas de Mercado

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 ene 2026, 20:27 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 ene 2026, 20:27 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 ene 2026, 20:27 UTC

Charlas de Mercado

Was It a 'TACO' Event? -- Market Talk

21 ene 2026, 20:26 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 ene 2026, 20:23 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 ene 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 ene 2026, 20:19 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Group Agrees to Buy Allfunds

21 ene 2026, 20:08 UTC

Ganancias

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 ene 2026, 20:03 UTC

Charlas de Mercado

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 ene 2026, 19:51 UTC

Charlas de Mercado

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 ene 2026, 19:43 UTC

Charlas de Mercado

U.S. Ethanol Production Expected to Slip -- Market Talk

21 ene 2026, 19:31 UTC

Charlas de Mercado

Gold Settles at Fresh All-Time High -- Market Talk

21 ene 2026, 19:24 UTC

Ganancias

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 ene 2026, 19:10 UTC

Charlas de Mercado

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 ene 2026, 18:57 UTC

Charlas de Mercado

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

49.78% repunte

Estimación a 12 Meses

Media 34 USD 49.78%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

159 / 361 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.